Myrcludex B: Completed Ph IIb MYR 203 enrollment

Hepatera and MYR completed enrollment of 60 patients in the open-label, Russian Phase IIb MYR 203 trial evaluating 2 mg Myrcludex B alone, 2 and 5 mg Myrcludex B plus pegylated interferon alpha-2a, an...